Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.
4.

[Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].

Westra TA, Daemen T, Postma MJ, Wilschut JC.

Ned Tijdschr Geneeskd. 2009;153:A356. Review. Dutch.

PMID:
19930733
5.

[Diseases caused by human papilloma viruses].

Zollner U, Schwarz TF.

Dtsch Med Wochenschr. 2011 May;136(20):1067-72. doi: 10.1055/s-0031-1275845. Review. German.

PMID:
21560109
6.

The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health.

Thomas TL.

Pediatr Nurs. 2008 Sep-Oct;34(5):429-31. Review.

PMID:
19051848
7.

Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases.

Skinner SR, Apter D, De Carvalho N, Harper DM, Konno R, Paavonen J, Romanowski B, Roteli-Martins C, Burlet N, Mihalyi A, Struyf F.

Expert Rev Vaccines. 2016;15(3):367-87. doi: 10.1586/14760584.2016.1124763. Review.

PMID:
26902666
8.

Cost–effectiveness of catch-up programs in human papillomavirus vaccination.

de Peuter MA, Littlewood KJ, Annemans L, Largeron N, Quilici S.

Expert Rev Vaccines. 2010 Oct;9(10):1187-201. doi: 10.1586/erv.10.108. Review.

PMID:
20923269
9.

Human papillomavirus quadrivalent vaccine: a look behind the numbers.

Flaherty DK, Alkhateeb FM.

Ann Pharmacother. 2009 Apr;43(4):740-4. doi: 10.1345/aph.1L483. Review.

PMID:
19276314
10.

AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.

Schwarz TF.

Expert Rev Vaccines. 2008 Dec;7(10):1465-73. doi: 10.1586/14760584.7.10.1465. Review.

PMID:
19053203
12.

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.

Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JM, Cummings T, Donovan B, Fairley CK, Flagg EW, Johnson AM, Kahn JA, Kavanagh K, Kjaer SK, Kliewer EV, Lemieux-Mellouki P, Markowitz L, Mboup A, Mesher D, Niccolai L, Oliphant J, Pollock KG, Soldan K, Sonnenberg P, Tabrizi SN, Tanton C, Brisson M.

Lancet Infect Dis. 2015 May;15(5):565-80. doi: 10.1016/S1473-3099(14)71073-4. Review.

13.
14.

Population impact of HPV vaccines: summary of early evidence.

Hariri S, Markowitz LE, Dunne EF, Unger ER.

J Adolesc Health. 2013 Dec;53(6):679-82. doi: 10.1016/j.jadohealth.2013.09.018. Review.

PMID:
24263069
16.

HPV vaccines to prevent cervical cancer and genital warts: an update.

Dochez C, Bogers JJ, Verhelst R, Rees H.

Vaccine. 2014 Mar 20;32(14):1595-601. doi: 10.1016/j.vaccine.2013.10.081. Review.

PMID:
24606637
17.

Strategies for continuous evaluation of the benefit-risk profile of HPV-16/18-AS04-adjuvanted vaccine.

Angelo MG, Taylor S, Struyf F, Tavares Da Silva F, Arellano F, David MP, Dubin G, Rosillon D, Baril L.

Expert Rev Vaccines. 2014 Nov;13(11):1297-306. doi: 10.1586/14760584.2014.959931. Review.

PMID:
25219284
18.

Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer.

Chelimo C, Wouldes TA, Cameron LD, Elwood JM.

J Infect. 2013 Mar;66(3):207-17. doi: 10.1016/j.jinf.2012.10.024. Review.

PMID:
23103285
19.

Human papillomavirus vaccines and vaccine implementation.

de Sanjosé S, Alemany L, Castellsagué X, Bosch FX.

Womens Health (Lond). 2008 Nov;4(6):595-604. doi: 10.2217/17455057.4.6.595. Review.

PMID:
19072462
20.

HPV vaccines: their pathology-based discovery, benefits, and adverse effects.

Nicol AF, de Andrade CV, Russomano FB, Rodrigues LS, Oliveira NS, Provance DW Jr, Nuovo GJ.

Ann Diagn Pathol. 2015 Dec;19(6):418-22. doi: 10.1016/j.anndiagpath.2015.07.008. Review.

PMID:
26321154
Items per page

Supplemental Content

Support Center